Article requires registration
Potential Cure for Covid-19 Pfizer, Biontech Secure ‘Fast Track’ for 2 Investigational Vaccine Candidates
The U.S. FDA has given the nod to Pfizer and Biontech to fast track two investigational mRNA-based vaccine candidates against Sars-Cov-2. Both the companies are expected to manufacture 100 million doses by the end of 2020, if it receives regulatory approval.
Mainz/Germany – Pfizer and Biontech have announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme (BNT162b1 and BNT162b2) being developed to help protect against Sars-Cov-2 (the virus that causes Covid-19), received the ‘Fast Track’ designation from the U.S. Food and Drug Administration (FDA).
BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 programme currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.